Evolus Holds Revenue Outlook, Trims Expense Plan
Suppliers and distributors in U.S. aesthetics should note the lower operating expense range paired with an unchanged sales target.
Updated on Nov. 6, 2026 in Corporate Finance
Evolus reaffirmed its 2026 revenue outlook of $330 million to $337 million while lowering its non-GAAP operating expense outlook to $210 million to $213 million. The changes matter for U.S. aesthetics-product suppliers and distributors tracking how a specialty injectables company is managing spending against sales targets.
Why it matters
Holding revenue steady while trimming expenses signals a focus on margin discipline rather than top-line expansion in 2026. For operators, the move shows how a company in the competitive aesthetics market is tightening its cost base after posting positive adjusted EBITDA for four straight quarters.
Evolus kept its 2026 revenue range at $330 million to $337 million and set non-GAAP operating expenses at $210 million to $213 million. The company also maintained a 67% to 67.5% adjusted gross margin outlook for the year.
The players
Evolus, Inc.
Evolus is a U.S.-based specialty aesthetics company that markets botulinum-toxin products for cosmetic use.
The details
Evolus reaffirmed its 2026 revenue range while lowering the expense range it expects to carry, which means the same sales forecast is now paired with a leaner cost assumption. The company also held its adjusted EBITDA margin outlook in the low- to mid-single digits. Its adjusted EBITDA has been positive for four straight quarters, indicating the company is currently operating profitably on an adjusted basis.
Timeline
2026: Revenue and expense outlook reaffirmed or revised for the year.
2028: Target revenue set at $450 million to $500 million.
Market Landscape
Evolus's 2028 revenue target of $450 million to $500 million sits well above its 2026 range of $330 million to $337 million, implying substantial planned growth. The company also plans three additional product introductions over the next four years, with Evolysse Sculpt expected to launch before Lips.
Operators in the aesthetics supply chain should expect the company to prioritize expense control while holding its sales target, which can affect pricing and promotional spending decisions. Businesses that depend on Evolus for product or distribution should watch whether the lower expense outlook persists into subsequent guidance updates.
The takeaway
The key insight is that Evolus is holding revenue expectations while tightening its cost structure, a pattern operators in specialty aesthetics should monitor against their own margin plans. Track the company's next quarterly report to see whether the lower operating expense range is reaffirmed.
Further reading
For more on how companies set and revise their financial outlooks, see Corporate Finance.
Source note: This article includes information reported by TokenPost.
